India: Food, Drugs, Healthcare, Life Sciences

India's food safety regulator has introduced mandatory vegan labelling standards requiring a uniform green logo on all plant-based food products. The new regulations establish precise technical specifications for the visual...

The Food Safety and Standards Authority of India has taken a significant step in fortifying the country’s food safety architecture by notifying the Food Safety and Standards (Contaminants, Toxins and Residues)...

In this episode of Podcast Bites by IndiaLaw LLP, host Tanvi Dalvi unpacks the sweeping reforms introduced under the FSSAI 2026 Amendment Regulations, effective 1 April 2026.

For years, the medical device industry has operated in a regulatory tug-of-war caught between the labelling requirements of the Legal Metrology (Packaged Commodities) Rules, 2011 & amendments thereof (“LM Rules”) and Medical Devices Rules, 2017 (“MD Rules”).

India's life sciences and healthcare sector saw significant regulatory shifts in April 2026, including proposed decriminalization of minor violations, new medical device testing fees, and streamlined foreign training requirements for healthcare professionals. Courts also delivered key rulings on pharmaceutical trademark disputes, reinforcing stricter standards for drug name similarity.

India's healthcare and pharmaceutical sectors are undergoing significant regulatory transformation through new frameworks for AI adoption, enhanced surveillance of drug supply chains, and streamlined approval processes.

India's life sciences and healthcare sector saw significant regulatory shifts in April 2026, including proposed decriminalization of minor violations, new medical device testing fees, and streamlined foreign training requirements for healthcare professionals. Courts also delivered key rulings on pharmaceutical trademark disputes, reinforcing stricter standards for drug name similarity.

Assume your doctor prescribes a drug to you. The brand-name version costs $300 a month. Another generic drug on the other hand will cost $30. As most people would, you would also purchase the cheaper one. That generic cheaper bottle exists as a result of a delicate legal balancing act, an act that the U.S. Supreme Court is now reconsidering in a case that could change pharmaceutical competition for decades.

The case raises a central question: to what extent can public interest influence the grant and scope of injunctive relief in cases involving deceptively similar medicinal trademarks?